Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The CDCCs are strategically positioned in regions identified as high-impact areas
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Sun Pharma Advanced Research Company has reported total income of Rs. 20.25 crores during the period ended December 31, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated